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Aims To determine whether changing patterns of anticoagulant use in atrial fibrillation (AF) have impacted on stroke
rates in England.
...................................................................................................................................................................................................
Methods
and results
English national databases, 2006–2016, were interrogated to assess stroke admissions and oral anticoagulant use. The
number of patients with known AF increased linearly from 692 054 to 983 254 (prevalence 1.29% vs. 1.71%). Hospital
episodes of AF-related stroke/100 000 AF patients increased from 80/week in 2006 to 98/week in 2011 and declined
to 86/week in 2016 (2006–2011 difference 18.0, 95% confidence interval (CI) 17.9–18.1, 2011–2016 difference -12.0,
95% CI -12.1 to -11.9). Anticoagulant use amongst patients with CHA2DS2-VASc >_2 increased from 48.0% to 78.6%
and anti-platelet use declined from 42.9% to 16.1%; the greatest rate of change occurred in the second 5 year period
(for anticoagulants 2006–2011 difference 4.8%, 95% CI 4.5–5.1%, 2011–2016 difference 25.8%, 95% CI 25.5–26.1%).
After adjustment for AF prevalence, a 1% increase in anticoagulant use was associated with a 0.8% decrease in the
weekly rate of AF-related stroke (incidence rate ratio 0.992, 95% CI 0.989–0.994). Had the use of anticoagulants
remained at 2009 levels, 4068 (95% CI 4046–4089) more strokes would have been predicted in 2015/2016.
...................................................................................................................................................................................................
Conclusion Between 2006 and 2016, AF prevalence and anticoagulant use in England increased. From 2011, hospitalized AF-
related stroke rates declined and were significantly associated with increased anticoagulant uptake.
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Introduction
Stroke is a major cause of deaths due to cardiovascular disease. For
strokes with an established aetiology, the substantial majority (87%)
are known to be ischaemic.1 Approximately one-third of ischaemic
strokes are associated with atrial fibrillation (AF).2 Strokes due to AF
are of particular significance as they are preventable with anticoagula-
tion.3 Recent international guidelines have lowered the threshold for
the use of oral anticoagulants and encouraged their use in preference
to anti-platelet drugs.4–6 Whether any resultant changes in prescrib-
ing practice have led to a reduction in AF-related stroke is unknown.
Existing evidence on temporal trends in AF-related stroke is con-
flicting. Data from earlier studies suggests a decline in strokes rates,
relating to increasing oral anticoagulant uptake,7,8 but more recent
studies have in general not indicated progressive benefit, perhaps due
to a levelling off of oral anticoagulant uptake.9–12 A particular prob-
lem for all studies lies in defining the prevalence of known AF and
oral anticoagulant uptake amongst the AF population at risk. This is
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especially important when both the prevalence and incidence of AF
are known to be increasing.13,14
The United Kingdom is unique in that a range of national primary
and secondary care databases exist, which have prospectively col-
lected consistent data fields relating to clinical care and health out-
comes over many years. We, therefore, used English multi-source
electronic health records data to investigate changes in the preva-
lence of known AF in primary care and hospital admissions for AF-
related stroke in England over 10 years between 2006 and 2016.
Specifically, we aimed to ascertain whether any changes in oral anti-
coagulant uptake were associated with temporal changes in AF-
related stroke.
Methods
Temporal trends of AF-related stroke, standardized to AF prevalence,
were compared with the uptake of oral anticoagulation over the 10 year
study period from 2006 to 2016. No single national database containing
all relevant information for this study exists. Therefore, a comprehensive
set of aggregated national data was compiled (see below and Figure 1).
Atrial fibrillation-related stroke
The number of episodes of hospitalized AF-related stroke in England
were accessed from the Hospital Episode Statistics (HES) data ware-
house.15 Aggregated weekly counts of the number of finished consultant
episodes with a primary diagnosis of stroke (ischaemic, haemorrhagic, or
unspecified) and secondary diagnosis of AF were extracted from inpatient
HES data between 1 April 2006 and 31 March 2016. A finished consultant
episode is the total time a patient spends under the care of an individual
consultant. Since transfer to a different consultant team would count as a
further episode, within each weekly period of record collection replicate
episodes relating to an individual patient were eliminated.
The pathogenesis of stroke was defined according to the International
Statistical Classification of Diseases and Related Health Problems (ICD-
10) codes as ischaemic (I63.0-I63.9), haemorrhagic (I61.0-I61.9), or un-
specified (I64.X). Strokes not coded as ischaemic or haemorrhagic were
also categorized as unspecified. Atrial fibrillation was defined as ICD
I48.X. The number of episodes of hospitalization with non-traumatic
intracranial bleeding (ICD I60.0-I60.9, I62.0, I62.1 and I62.9) as a primary
diagnosis and AF as a secondary diagnosis was also determined.
Charlson co-morbidity index categories I–III, based on myocardial in-
farction, heart failure, peripheral vascular disease, dementia, cerebrovas-
cular disease, chronic lung disease, connective tissues disease, peptic
ulcer disease, liver disease, diabetes, kidney disease, cancer, and HIV were
calculated from HES data for all patients with a primary diagnosis of
stroke and secondary diagnosis of AF.16,17
Atrial fibrillation prevalence
The English national prevalence of AF was derived from the Clinical
Domain of the Quality and Outcomes Framework (QOF) database for
England (https://digital.nhs.uk/Quality-and-Outcomes-Framework/QOF).
QOF is a national primary care database covering all primary care practi-
ces (n= 8372 practices for 2006/2007; n= 7619 for 2015/2016) in
England and collects prevalence and treatment data for a number of
Figure 1 STROBE diagram of the derivation of the analytical cohorts and their associated timeframes. HES: Hospital Episode Statistics; QOF:
Quality and Outcomes Framework; GRASP: Guidance on Risk Assessment for Stroke Prevention in AF; Holt et al.20
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conditions including AF. Data are gathered from individual practices at
the end of March each year. De-identified QOF AF data, aggregated by
practice and summarised at national level, were accessed from 1 April
2006 to 31 March 2016.
Oral anticoagulation
De-identified patient data, aggregated to annual rates, concerning uptake
of oral anticoagulants for patients living in England with a moderate to
high risk of stroke measured as either a CHADS2 score >_2 (1 April 2012
to 1 April 2015), or a CHA2DS2-VASc score >_2 (1 April 2015 to 1 April
2016) were accessed from QOF.18,19 Given that prior to 1 April 2012 no
single national data source was available for oral anticoagulant use, we
used information from two large English cohorts to construct a timeline
of national oral anticoagulant and anti-platelet drug use. This comprised
(i) data from a published primary care series between 2007 and 2010
(99 351 patients from 583 general practices in England) and (ii) the
Guidance on Risk Assessment for Stroke Prevention in AF (GRASP-AF)
tool of the National Health Service Improving Quality (NHSIQ) and
PRIMIS, University of Nottingham, between 2009 and 2016 (414 560
patients from 3162 general practices in England).20,21 These data were
aggregated and weighted according to cohort size. In addition, informa-
tion about the type of oral anticoagulant, vitamin K antagonist or direct
oral anticoagulant (DOAC), was extracted for the GRASP-AF cohort be-
tween 2011 and 2016.
Statistical analyses
Patient and clinical demographics for hospitalized AF-related stroke
recorded in HES were described according to biennial period as well as
overall between 2006 and 2016. Data from QOF, including the total num-
ber of AF cases and AF prevalence were described over the same time
periods. Absolute differences alongside 95% confidence intervals (CIs) be-
tween the first and last biennial period were calculated for each variable.
The significance of linear time trends over the full period were assessed
using logistic and linear regression models for categorical and continuous
variables, respectively. In addition, we provide supplementary information
on the differences in baseline variables between study periods calculated
using the Difference-in-Difference (DiD) technique. Differential time effect
and CIs were estimated using a fixed effect model for each baseline variable
between two study periods (2006–2011 and 2011–2016).
The weekly rate of AF-related stroke per 100 000 patients with AF was
standardized by dividing the weekly number of AF-related strokes by the
weekly national AF prevalence derived from fitting a polynomial regression
to the QOF annual data. The primary statistical analysis was based on
weekly counts of hospitalized AF-related stroke. Although the weekly
counts eliminate patient replicates within each week, they may reflect dif-
ferent stages in stroke management and not just the acute admission. To
address this, we assessed stroke counts based on annual AF-related stroke
admissions obtained from a second extract of HES data with the same
specifications, but with aggregation to whole calendar years (2007–2015)
and episode replicates eliminated over an annual timeframe.
To model the rate of hospitalized AF-related stroke and its association
with the use of oral anticoagulants or anti-platelet drugs, a series of
Poisson regression models were fitted. Initially, the unadjusted association
of AF-related stroke with the percentage of oral anticoagulant usage was
calculated in a univariate model. Subsequently, models were incremental-
ly adjusted for temporal trends per week, including second and third de-
gree polynomials of time to model non-linear associations. In addition,
we included sine curves to model seasonality, as well as AF prevalence
and patient demographics including sex, age in years, and Charlson Co-
morbidity Index categories I to III. Results were presented as incidence
rate ratios (IRRs) and 95% CIs.
To ascertain the potential influence of time variance in the reallocation
of non-specified AF-related stroke pathology (because of, for example,
changes in the use of cerebral imaging to enable greater diagnosis of is-
chaemic stroke), we conducted a sensitivity analysis of the above statistic-
al analyses after re-classification of non-specified strokes to ischaemic and
haemorrhagic strokes and compared the results with those of the main
analyses.
All tests were two-sided, and statistical significance was considered
P< 0.05. Statistical analyses were performed in R version 3.1.2 (https://
cran.r-project.org/).
Results
The AF-related stroke analytical cohort (n= 375 310) was drawn
from 1 291 757 hospitalized finished consultant episodes with a pri-
mary diagnosis of stroke in England between 1 April 2006 and 31
March 2016 (Figure 1). These episodes were derived from the corre-
sponding period of HES data for all hospitalizations in England (n =
150 million hospital episodes).15,22 Of all hospitalized finished con-
sultant episodes of AF-related stroke, there were 294 510 (78.5%) is-
chaemic strokes, 31 770 (8.5%) haemorrhagic strokes, and 49 030
(13.0%) non-specified strokes. In total, there were 165 485
hospitalized episodes of intracranial bleeds of which 24 355 (14.9%)
had a secondary diagnosis of AF. Of patients with AF-related stroke,
157 255 (41.9%) were men, mean age was 81.1 years, 100 891
(26.9%) were in the lowest (I), 32 879 (8.8%) in the middle (II), and
73 922 (19.7%) in the highest Charlson co-morbidity index category
(Table 1). Temporal trends in co-morbidities of AF-related stroke are
described in more detail in Supplementary material online, Table S1.
Over the 10 years, there were on average 814 501 cases of AF
each year (prevalence 1.43%) across 7995 general practice surgeries
in England. During this period, on average 57.2% patients with AF and
a CHA2DS2-VASc score >_2 received oral anticoagulation.
Temporal trends in atrial fibrillation
prevalence
From 2006 to 2016, the number of patients with AF increased from
692 054 to 983 254 [prevalence 1.29% vs. 1.71%; absolute difference
(AD) 0.42%, 95% CI 0.41–0.43%] (Figure 2, Table 1). The rate of in-
crease in the prevalence of AF was similar in the first 5 year period
2006–2011 and the second 5 year period 2012–2016 (0.20%, 95% CI
0.16–0.24% vs. 0.22%, 95% CI 0.18–0.26%, Supplementary material
online, Table S2).
Temporal trends in atrial fibrillation-
related stroke
The numbers of hospitalized finished consultant episodes of AF-
related stroke per week demonstrated regular changes each year in
keeping with seasonality (Figure 2). Between 2006 and 2011, the rates
of hospitalized finished consultant episodes of AF-related stroke per
100 000 patients with AF increased from 80 to 98 per week (differ-
ence 18.0, 95% CI 17.9–18.1) and declined to a rate of 86 per week in
2016 (difference 2011–2016: -12.0, 95% CI -12.1 to -11.9) (Figure 3
and Supplementary material online, Table S2).
The proportion of patients with AF-related stroke who were not
classified as either ischaemic or haemorrhagic decreased from 24.5%
A 10 year study of hospitalized atrial fibrillation-related stroke in England 3
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in 2006 to 6.4% in 2016 (see Supplementary material online, Figure S1).
The temporal trend in ischaemic stroke is presented in Figure 4 to-
gether with the combined endpoint of haemorrhagic stroke and
intracranial bleeding. Over the study period, there was a slight
increase in the rates of the combined endpoint of cerebral haemor-
rhage and intracranial bleeding per 100 000 patients with AF (from
10.5 per week in 2006 to 14.4 per week in 2016, AD: 3.9
per week, 95% CI 3.6–4.2; 2011–2016 AD 0.4 per week, 95% CI 0.0–
0.7, Figure 4).
Temporal trends in the use of oral
anticoagulants and antiplatelet drugs
From 2006 to 2016, the use of oral anticoagulants among patients with
AF and a CHA2DS2-VASc score >_2 increased from 48.0% to 78.6%
(AD: 30.6%, 95% CI 30.2–31.0%) (Figure 3) (For a comparison of
CHADS2 and CHA2DS2-VASc based anticoagulant uptake, see
Supplementary material online, Figure S2). The greatest rate of change
in the use of anticoagulants occurred in the latter 5 year period (2006–
2011 AD 4.8%, 95% CI 4.5–5.1%, 2011–2016 AD 25.8%, 95% CI 25.5–
26.1%) (see Supplementary material online, Table S2). Amongst
patients with CHA2DS2-VASc >_2 in the GRASP cohort, the use of
DOACs increased from 0.1% of the oral anticoagulant group in 2011
to 32.5% in 2016 (Figure 5).
Over the study period, the use of anti-platelet drugs among
patients with AF and a CHA2DS2-VASc score >_2 decreased from
42.9% to 16.1% (AD -26.8%, 95% CI -27.3% to -26.3%) (Figure 3).
The greatest rate of change in the use of antiplatelet drugs for AF
occurred in the latter 5 year period (2006–2011 AD -5.2%, 95% CI
-5.5% to -4.9%, 2011–2016 AD -21.6%, 95% CI -22.1% to -21.1%)
(see Supplementary material online, Table S2).
Association between changing use of oral
anticoagulants and anti-platelet drugs
and atrial fibrillation-related stroke
Without adjustment, the use of oral anticoagulants demonstrated a
significant 2.1% increase in finished consultant episodes of AF-related
stroke (Table 2) (IRR 1.021, 95% CI 1.019–1.022). With adjustment
for AF prevalence, sex, age, and co-morbidity, the effect was reversed
suggesting that a 1% increase in the use of oral anticoagulants among
.....................................................................................................................................................................
....................................................................................................................................................................................................................
Table 1 Patient characteristics by period of study
Characteristic Period of study
2006–2016 2006/2008a 2008/2010 2010/2012 2012/2014 2014/2016 Difference:
2014/2016–
2006/2008
(95% CI)
P-trend
Hospitalized finished consultant episodes of AF-related strokeb
All stroke patients 375 310 57 874 69 817 78 795 84 159 84 665 26 791 0.014
Male 157 255 (41.9) 23 439 (40.5) 28 066 (40.2) 32 621 (41.4) 35 599 (42.3) 37 676 (44.5) 4.0 (3.5, 4.5) 0.025
Age (years), mean 81.12 80.74 81.12 81.12 81.17 81.35 0.61 (0.18, 1.04) 0.036
Deaths in hospital 57 360 (15.3) 10 741 (18.6) 11 713 (16.8) 11 606 (14.7) 11 703 (13.9) 11 597 (13.7) -4.9 (-5.3,-4.5) 0.012
Charlson Comorbidity Index
Category I 100 891 (26.9) 16 747 (28.9) 18 667 (26.7) 21 617 (27.4) 22 453 (26.7) 21 407 (25.3) -3.7 (-4.1,-3.1) 0.055
Category II 32 879 (8.8) 4486 (7.8) 5441 (7.8) 6987 (8.9) 7931 (9.4) 8034 (9.5) 1.7 (1.9, 2.0) 0.015
Category III 73 922 (19.7) 9006 (15.6) 11 353 (16.3) 15 673 (19.9) 18 315 (21.8) 19 575 (23.1) 7.6 (7.1, 7.9) 0.003
Stroke classification
Ischaemic 294 510 39 976 51 444 62 024 69 855 71 211 31 235 0.006
Haemorrhagic 31 770 4678 5504 6438 7179 7971 3293 <0.001
Intracranial bleeding 24 355 3381 4108 5086 5671 6109 2728 0.001
Quality and Outcomes Frameworkc
Total AF 814 501 696 605 747 236 807 090 866 672 954 902 258 297 <0.001
Population AF prevalence (%) 1.43 1.29 1.37 1.46 1.54 1.67 0.38 (0.34, 0.42) <0.001
Weekly stroke incidence
per 100 000 AF
91 80 92 98 95 88 8 (7.9, 8.1) 0.47
Medicationd
Proportion of OAC use (%) 55.8 48.0 49.7 52.5 58.7 70.2 22.2 (22.1, 22.4) <0.001
Proportion of antiplatelet
drug use (%)
33.1 43.1 41.2 35.4 28.8 17.1 -26.0 (-26.6, 25.4) <0.001
AF, atrial fibrillation; GRASP, Guidance on Risk Assessment and Stroke Prevention in AF; OAC, oral anticoagulants; QOF, Quality and Outcomes Framework.
aTwo financial years between 1 April 2006 and 31 March 2008.
bFor HES data, the accumulated number of AF-related stroke and percentage were reported unless specified.
cFor QOF prevalence data, the mean estimated from the fitted regression model was reported for each period.
dMedication uptake data from Holt et al.,20 QOF, and GRASP was used. A weighted regression model was fitted to the use of OAC and antiplatelet drugs separately. The mean
estimated from the regression model was reported for each period.
4 J.C. Cowan et al.
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..patients with AF and a CHA2DS2-VASc score >_2 was associated
with a decline of 0.8% in weekly hospitalized AF-related strokes (IRR
0.992, 95% CI 0.989–0.994).
When the use of anti-platelet drugs was modelled rather than
the use of oral anticoagulants (see Supplementary material
online, Table S3), there was a negative association between the
use of anti-platelet drugs and stroke (IRR 0.980, 95% CI 0.979–
0.981). With adjustment for AF prevalence, sex, age, and co-
morbidity, this effect was reversed (IRR 1.033, 95% CI 1.028–
1.038).
Figure 2 Temporal trend in finished consultant episodes of atrial fibrillation-related stroke and national prevalence of atrial fibrillation.
Figure 3 Temporal trend in finished consultant episodes of atrial fibrillation-related stroke per 100 000 patients with atrial fibrillation and uptake of
oral anticoagulants and anti-platelet drugs for patients with atrial fibrillation and a CHA2DS2VASc score >_2. The anticoagulant timeline is a weighted
trend derived from Holt et al.,20 GRASP AF,21 and Quality and Outcomes Framework.
A 10 year study of hospitalized atrial fibrillation-related stroke in England 5
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Sensitivity analyses
To determine the impact of the temporal changes in the decrease of
unspecified diagnoses, we conducted a sensitivity analyses in which
10% of the unspecified diagnoses were reallocated as ‘haemorrhagic’
and 90% were reallocated as ‘ischaemic’. This analysis did not alter the
direction or magnitude of the final model estimates (IRR 0.996, 95% CI
0.994–0.998) (see Supplementary material online, Tables S4 and S5,
Figure S3).
When AF-related stroke rates were considered over an annual time
frame (see Supplementary material online, Table S6 and Figures 4) and
the ratio of the annual sum of weekly strokes to the annual timeframe
was calculated, the ratio did not show a significant trend with time.
Magnitude of anticoagulant benefit
The number of hospitalized AF-related strokes in 2015/16 was
42 296 (95% CI 41 663–42 929). This was estimated to represent 4,
068 (95% CI 4046–4089) fewer hospitalized AF-related strokes than
would have been predicted had oral anticoagulation rates remained
at the 2009 level (49% in 2009 vs. 79% in 2015/16) (For details of the
calculation, see Supplementary material online, Section 2).
Figure 4 The temporal trend of atrial fibrillation-related stroke stratified by stroke pathogenesis.
6 J.C. Cowan et al.
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Discussion
In this analysis of national multi-source electronic health records be-
tween 2006 and 2016, we found that an increase in the nationwide
uptake of oral anticoagulants in patients with AF and a CHA2DS2-
VASc score >_2 was significantly associated with a decline in
hospitalized AF-related stroke.
To date, time course studies of temporal changes in AF-related
stroke have reached differing conclusions. Data from the
Framingham population found a decline in risk of stroke occurring
following the onset of AF between 1958 and 2007.7 Data from
Medicare between 1992 and 2007 also reported a decline in stroke
rates amongst patients with AF, coinciding with a doubling of oral
anticoagulant uptake.8 In contrast, another US study found that rates
of stroke and transient ischaemic attacks remained unchanged be-
tween 2000 and 2010, which was attributed to a plateauing of oral
anticoagulant use.9 A UK study found no reduction in AF-related
stroke and other embolic vascular events between 2002 and 2012.10
Two Asian studies have shown either a progressive rise in AF-related
stroke or a biphasic trend.11,12 Evidence from the SENTINEL data-
base of stroke admissions in England, between 2013 and 2017,
showed the proportion of strokes with known antecedent AF was
constant at approximately 20%, despite a rising proportion receiving
prior oral anticoagulation.23
Our study extends previous investigations by combining national
information on incident stroke with the national prevalence of known
AF. From 2011 to 2016, we found a nationwide shift in clinical prac-
tice reflected in an increased use of oral anticoagulants and a corre-
sponding decrease in the use of anti-platelet drugs among patients
with AF and a CHA2DS2-VASc score >_2. While it is not possible to
attribute this change in practice to a single cause, guideline changes,
quality improvement initiatives and the advent of DOACs may have
been contributory. Notably, European Society of Cardiology (ESC)
and NICE guidelines were published and subsequently revised during
..................................................................................................................................... ..............................
......................................................................................................................................................................................................................
Table 2 Association between weekly rates of hospitalized finished consultant episodes of AF-related stroke and the
use of oral anticoagulants, adjusted for AF prevalence and patient characteristics
Model Use of oral anticoagulants (%) AIC and BIC
Incident rate ratio (95% CI) P-value Absolute difference in rates (95% CI) AIC BIC
Unadjusted use of OAC 1.021 (1.019–1.022) <0.001 0.021 (0.019 to 0.021) 11 749.2 11 757.7
Use of OAC adjusted for
AFˆ 0.955 (0.954–0.958) <0.001 -0.045 (-0.046 to -0.043) 6222.6 6235.3
AF, sex, and age 0.959 (0.957–0.961) <0.001 -0.041 (-0.045 to -0.041) 6142.6 6163.8
AF, sex, age, and CCI 0.992 (0.989–0.994) <0.001 -0.008 (-0.011 to -0.006) 5120.5 5154.5
AF, atrial fibrillation; AFˆ refers to total national AF prevalence derived from QOF data; AIC, Akaike Information Criteria; BIC, Bayesian Information Criteria; CCI, Charlson
Comorbidity Index; OAC, oral anticoagulants.
Figure 5 Direct oral anticoagulant uptake (as a percentage of all those taking an oral anticoagulant) amongst patients with CHA2DS2-VASc >_2 in
the GRASP cohort.
A 10 year study of hospitalized atrial fibrillation-related stroke in England 7
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..the course of this study, with decreasing emphasis or complete re-
moval of recommendations for the use of antiplatelet drugs amongst
lower risk patients.4–6 In the UK, evidence for the underutilisation of
oral anticoagulants led to national quality improvement initiatives to
improve their uptake.20,21,24 For example, GRASP-AF was imple-
mented as a national service improvement tool in 2009 to improve
oral anticoagulant uptake.21 In 2012, changes to QOF incentivised
general practitioners to use oral anticoagulants in preference to anti-
platelet agents for patients with a CHADS2 score >_2. In addition the
advent of DOACs, together with the publicity and marketing associ-
ated with their introduction, may have contributed to increased up-
take of oral anticoagulants. The first DOAC agent was licensed for
stroke prophylaxis in AF in the UK in 2011. Following their introduc-
tion, the use of DOACs increased progressively, coinciding with the
increase in oral anticoagulant uptake in the second half of the study
period. A similar progressive rise in DOAC uptake has been reported
by other studies.25,26 Increasing DOAC use may also contribute to
increased oral anticoagulant uptake through increased therapy per-
sistence in comparison with the use of vitamin K antagonists.25
Direct oral anticoagulants reduce the frequency of cerebral haem-
orrhage and intracranial bleeding in comparison with warfarin.27
Although a small increase in intracranial bleeding and haemorrhagic
stroke was observed in the 10 year period overall, there was no sig-
nificant change in the latter 5 year period when the increase in uptake
of oral anticoagulants was most pronounced. This may reflect the
increasing use of DOACs.
Whilst this study has strengths such as single national health sys-
tem coverage over a decade, we acknowledge its limitations. The
data were aggregated and not linked, and we were unable to track in-
dividual patients or include all possible confounding factors over the
study period. This aggregation could lead to a potential ‘ecological fal-
lacy’ in which the findings are attributed incorrectly to the individual
patient level; that is, one cannot assume that our findings are
applicable to individual patients. In addition, we only had co-
morbidity data for cases of AF-related stroke and not for the popula-
tion at risk. Our primary outcome of hospitalized AF-related stroke
will not have counted cases of stroke that were managed in the com-
munity or cases that died prior to hospitalization. We had no infor-
mation on the timing of the AF identified as a secondary diagnosis.
Our analysis was based on weekly rates of finished consultant epi-
sodes rather than unique hospital admissions with stroke, although a
sensitivity analysis over an annual timeframe suggested that the
observed temporal trends reflected stroke incidence. Although more
stroke patients received diagnostic imaging in the latter years, a sensi-
tivity analysis exploring this did not change the overall study
conclusions.
The uptake of oral anticoagulants for stroke prophylaxis varies
internationally and tends, for example, to be higher in Europe and
Japan than in the USA and the rest of Asia.3,28 Our analysis suggests
that for communities with modest anticoagulant uptake, increasing
uptake offers considerable potential for stroke reduction.29 For com-
munities already achieving a high level of oral anticoagulant use, the
potential for further gains through increasing uptake can only wane
due a ‘ceiling effect’ from a residual core of patients with contraindi-
cations. In these communities, particular attention to enhancing iden-
tification of unrecognized AF, whether through improving clinical
detection or electrocardiogram monitoring strategies,30 may be
justified.
In conclusion, we have observed an association between an in-
crease in oral anticoagulant uptake and a decline in AF prevalence
corrected stroke rate in England. While our study reports only a de-
scriptive association and cannot demonstrate causality, our analysis
suggests that increase in anticoagulant uptake contributed to a reduc-
tion of some 4000 strokes in England in 2015/2016 in comparison
with projected stroke rates if the use of oral anticoagulants had
remained constant at 2009 levels.
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